Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jeremy Pascotto

Orthopaedic Surgery Charlotte, MI Doctor of Osteopathy

NPI 1548498140 CMS profile 577917

123 Lansing St, Suite 2, Charlotte, MI 48813

Open in the dashboard

General payments

$4,469

100 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jeremy Pascotto of Charlotte, MI is reported in the CMS Open Payments database as having received $4,469 across 100 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 54th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $154 6
2024 General $277 8
2023 General $1,894 11
2022 General $1,265 12
2021 General $10 1
2020 General $227 30
2019 General $643 32

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jeremy Pascotto
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Jeremy Pascotto were reported at $154. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Jeremy Pascotto Orthopaedic Surgery median Middle half National median
2019 $643 $644 $140–$2,844 $163
2020 $227 $312 $75–$1,860 $114
2021 $10 $520 $117–$2,495 $132
2022 $1,265 $598 $128–$2,731 $149
2023 $1,894 $461 $128–$2,264 $160
2024 $277 $497 $134–$2,475 $164
2025 $154 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Encore Medical, LP $2,338 7 payments
  2. Stryker Corporation $505 7 payments
  3. Smith+Nephew, Inc. $338 3 payments
  4. Horizon Therapeutics plc $285 42 payments
  5. Ferring Pharmaceuticals Inc. $239 14 payments
  6. Djo, LLC $226 2 payments
  7. Flexion Therapeutics, Inc. $93 4 payments
  8. Zimmer Biomet Holdings, Inc. $85 3 payments
  9. Bioventus LLC $83 5 payments
  10. Boston Scientific Corporation $63 1 payment
  11. Other $216 12 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,440 96 payments
  2. Travel and Lodging $2,029 4 payments
Products named General payments · program years 2019–2025
  1. DJO SURGICAL Joint Implants $1,123 5 payments
  2. DJO SURGICAL Joint Implants $959 4 payments
  3. DJO SURGICAL Joint Implants $789 1 payment
  4. DJO SURGICAL Joint Implants $426 1 payment
  5. DJO SURGICAL Joint Implants $423 4 payments
  6. Bone Anchors with Arthroscopic Delivery System $280 2 payments
  7. Bioinductive Implant with Arthroscopic Delivery System - Medium $280 2 payments
  8. EUFLEXXA $239 14 payments
  9. T2 ALPHA $163 1 payment
  10. DUEXIS $143 22 payments
  11. Other $1,098 55 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

745

Median for Orthopedic Surgery: 203

Drug cost

$22,252

Median for Orthopedic Surgery: $1,433

Branded share of claims

11.7%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Protriptyline Hcl Generic 13 $11,306
Calcipotriene Generic 11 $3,450
Celecoxib Generic 173 $3,379
Diclofenac Sodium Generic 27 $1,462
Methylprednisolone Generic 167 $1,110
Mupirocin Generic 75 $444
Chlorhexidine Gluconate Generic 74 $326
Cefdinir Generic 18 $291
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 47 $164
Meloxicam Generic 26 $94

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 49 billing codes

Paid by Medicare

$77,393

Of which drugs: $12,123

Medicare patients

187

Average age 71

Services billed

991

115 women, 72 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 74%
Depression 32%
Diabetes 30%
COPD 23%
Ischemic heart disease 22%
Chronic kidney disease 18%
Heart failure 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, euflexxa, for intra-articular injection, per dose J7323 Office 27 102 $9,277
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 80 244 $1,240

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

100 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record